Back
Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines.
Journal article

Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines.

  • Valiente M Brain Metastasis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. mvaliente@cnio.es.
  • Van Swearingen AED Duke Center for Brain and Spine Metastasis, Duke Cancer Institute, Durham, North Carolina.
  • Anders CK Duke Center for Brain and Spine Metastasis, Duke Cancer Institute, Durham, North Carolina.
  • Bairoch A CALIPHO group, Swiss Institute of Bioinformatics, Geneva, Switzerland.
  • Boire A Human Oncology and Pathogenesis Program, Department of Neurology, Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Bos PD Department of Pathology, and Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
  • Cittelly DM Department of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Erez N Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Ferraro GB E.L. Steele Laboratories, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.
  • Fukumura D E.L. Steele Laboratories, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.
  • Gril B NCI, Bethesda, Maryland.
  • Herlyn M Molecular & Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania.
  • Holmen SL Huntsman Cancer Institute and Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, Utah.
  • Jain RK E.L. Steele Laboratories, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts.
  • Joyce JA Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.
  • Lorger M Brain Metastasis Research Group, School of Medicine, University of Leeds, Leeds, United Kingdom.
  • Massague J Cancer Cell Biology Program, Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Neman J Departments of Neurological Surgery, Physiology & Neuroscience, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Sibson NR Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom.
  • Steeg PS NCI, Bethesda, Maryland.
  • Thorsen F The Molecular Imaging Center, Department of Biomedicine, University of Bergen, Bergen, Norway.
  • Young LS Endocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Varešlija D Endocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Vultur A Molecular & Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania.
  • Weis-Garcia F Antibody & Bioresource Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Winkler F Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, and Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Show more…
  • 2020-07-10
Published in:
  • Cancer research. - 2020
English Spread of cancer to the brain remains an unmet clinical need in spite of the increasing number of cases among patients with lung, breast cancer, and melanoma most notably. Although research on brain metastasis was considered a minor aspect in the past due to its untreatable nature and invariable lethality, nowadays, limited but encouraging examples have questioned this statement, making it more attractive for basic and clinical researchers. Evidences of its own biological identity (i.e., specific microenvironment) and particular therapeutic requirements (i.e., presence of blood-brain barrier, blood-tumor barrier, molecular differences with the primary tumor) are thought to be critical aspects that must be functionally exploited using preclinical models. We present the coordinated effort of 19 laboratories to compile comprehensive information related to brain metastasis experimental models. Each laboratory has provided details on the cancer cell lines they have generated or characterized as being capable of forming metastatic colonies in the brain, as well as principle methodologies of brain metastasis research. The Brain Metastasis Cell Lines Panel (BrMPanel) represents the first of its class and includes information about the cell line, how tropism to the brain was established, and the behavior of each model in vivo. These and other aspects described are intended to assist investigators in choosing the most suitable cell line for research on brain metastasis. The main goal of this effort is to facilitate research on this unmet clinical need, to improve models through a collaborative environment, and to promote the exchange of information on these valuable resources.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/13214
Statistics
Document views: 65 File downloads: